Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 1274 for:    IFNA2

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01460875
Recruitment Status : Completed
First Posted : October 27, 2011
Results First Posted : November 2, 2018
Last Update Posted : November 2, 2018
Sponsor:
Collaborator:
Schering-Plough
Information provided by (Responsible Party):
William Carson, Ohio State University Comprehensive Cancer Center

Tracking Information
First Submitted Date  ICMJE October 25, 2011
First Posted Date  ICMJE October 27, 2011
Results First Submitted Date  ICMJE May 4, 2018
Results First Posted Date  ICMJE November 2, 2018
Last Update Posted Date November 2, 2018
Actual Study Start Date  ICMJE April 22, 2008
Actual Primary Completion Date January 5, 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 31, 2018)
Level of Activated STAT1(Phospho-STAT1) [ Time Frame: up to 4 weeks ]
Mean and 95% confidence interval will be summarized for phospho-STAT1 at a lower dose and the standard dose. The phospho-STAT1 will also be compared between the dose levels.
Original Primary Outcome Measures  ICMJE
 (submitted: October 25, 2011)
Selection of the optimal recombinant interferon alfa-2b dose using signal transduction data [ Time Frame: Every 2 weeks for 4 weeks ]
Accomplished through a one-sided confidence interval on the difference between observed response at a lower dose and the observed response at the standard dose. If we cannot declare non-inferiority for a dose, the patient will go back to the lowest dose at which non-inferiority can be claimed.
Change History Complete list of historical versions of study NCT01460875 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 31, 2018)
  • Number of Patients With Adverse Events [ Time Frame: up to 1 year ]
    Determine the tolerability of adjuvant IFN-α-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.
  • Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation [ Time Frame: Prior to treatment and 1 and 4 hours post therapy on day 1 every other week during the first 12 weeks, and then every 3 months ]
    Levels of p-STAT1 in PBMCs were analyzed just prior to IFN-a-2b administration to determine levels that remained stable or increased over the course of dose reduction.
  • Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes [ Time Frame: 1 hour post therapy ]
    Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 10MU/m2
  • Effect of Dose-reduction on Interferon Alfa Gene Expression [ Time Frame: 1 hour post therapy ]
    Evaluated using microarray analysis of patient PBMCs. Compared using the Wilcoxon signed rank test for the dose 4MU/m2
  • Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69 [ Time Frame: 4 hours post therapy ]
    Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.
  • Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU [ Time Frame: 4 hours post therapy ]
    Evaluated using microarray analysis of patient PBMCs. Compared between doses using the Wilcoxon signed rank test.
  • Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates [ Time Frame: Baseline and every other week prior to recombinant interferon alfa-2b administration ]
    Define the clinical role of tumor sensitivity to IFN-α, patient tumor biopsies taken prior to the administration of IFN-α will be systematically evaluated for cellular levels of Jak-STAT signaling intermediates.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 25, 2011)
  • Tolerability of adjuvant recombinant interferon alfa-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy [ Time Frame: Every 2 weeks ]
  • Correlation between STAT1 phosphorylation and interferon alfa gene regulation [ Time Frame: Prior to treatment and 1 and 4 hours post therapy on day 1 every other week during the first 12 weeks, and then every 3 months ]
  • Effect of Dose-reduction on Interferon Alfa Gene Expression [ Time Frame: Prior to treatment and 1 and 4 hours post therapy on day 1 every other week during the first 12 weeks, and then every 3 months ]
  • Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates [ Time Frame: Baseline and every other week prior to recombinant interferon alfa-2b administration ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Official Title  ICMJE Pilot Study of IFN-alpha-2b Dose Reduction With Dose Optimization
Brief Summary This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma
Detailed Description

PRIMARY OBJECTIVES:

I. To determine whether selection of the optimal IFN-alpha-2b (recombinant interferon alfa-2b) dose can be made using signal transduction data.

SECONDARY OBJECTIVES:

I. To determine the tolerability of adjuvant IFN-alpha-2b administered at an optimized dose in terms of the toxicities that are observed and the ability of patients to receive a full year of therapy.

II. The transcription of a panel of IFN-alpha-induced genes previously identified by microarray analysis will be determined by Real-Time reverse transcriptase-polymerase chain reaction (RT PCR) in order that the correlation between signal transducer and activator of transcription 1 (STAT1) phosphorylation and IFN-alpha gene regulation can be evaluated.

III. Microarray analysis of patient peripheral blood mononuclear cells (PBMCs) will be used to evaluate the effect of dose-reduction on IFN-alpha gene expression.

IV. In order to define the clinical role of tumor sensitivity to IFN-alpha, patient tumor biopsies taken prior to the administration of IFN-alpha will be systematically evaluated for cellular levels of janus kinase (Jak)-STAT signaling intermediates.

OUTLINE:

Patients receive recombinant interferon alfa-2b subcutaneously (SC) thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3-6 months for 2 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Stage IA Skin Melanoma
  • Stage IB Skin Melanoma
  • Stage IIA Skin Melanoma
  • Stage IIB Skin Melanoma
  • Stage IIC Skin Melanoma
  • Stage IIIA Skin Melanoma
  • Stage IIIB Skin Melanoma
  • Stage IIIC Skin Melanoma
  • Stage IV Skin Melanoma
Intervention  ICMJE
  • Biological: recombinant interferon alfa-2b
    Given SC
    Other Names:
    • Alfatronol
    • Glucoferon
    • Heberon Alfa
    • IFN alpha-2B
    • Intron A
  • Other: laboratory biomarker analysis
    Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
    Other Name: Correlative studies
Study Arms  ICMJE Experimental: Treatment (interferon therapy)
Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Biological: recombinant interferon alfa-2b
  • Other: laboratory biomarker analysis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 31, 2018)
34
Original Actual Enrollment  ICMJE
 (submitted: October 25, 2011)
35
Actual Study Completion Date  ICMJE January 5, 2014
Actual Primary Completion Date January 5, 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must be considered a candidate for adjuvant IFN-alpha-2b therapy after having undergone successful surgery for high-risk melanoma (Breslow thickness > 4 mm or lymph node disease) or complete resection of metastatic disease; definitive surgery should have been accomplished no greater than 90 days prior to start of treatment with intravenous IFN-alpha-2b
  • Patients must have completed 20 treatments of intravenous IFN-alpha-2b according to standard practice within 2 months of beginning treatment on this study
  • Patients must have not have any evidence of persistent or recurrent disease as determined by the appropriate radiologic imaging techniques
  • Patients may have received prior IFN-alpha therapy for metastatic disease, but more than 6 months must have passed between the last dose of IFN-alpha therapy for metastatic disease and the first dose of intravenous IFN-alpha-2b; patients who have had prior interleukin (IL)-2 are eligible for this study
  • Patients may have received radiation therapy after intravenous IFN-alpha-2b; they may begin subcutaneous dosing of IFN-alpha-2b on this study after the radiation therapy has been completed; the patient may initiate dose reductions after the last radiation treatment as long as the appropriate amount of time has passed
  • Life expectancy of greater than 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 70%)
  • Leukocytes >= 3,000/ul
  • Absolute neutrophil count >= 1,500/ul
  • Platelets >= 100,000/ul
  • Total bilirubin =< 2.0 (Gilbert's disease permitted)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) < 3 x institutional upper limit of normal
  • Creatinine =< 1.5 and stable OR
  • Creatinine clearance >= 60 mL.min/1.73 m^2 for patients with creatinine levels above normal
  • Pulse oximetry >= 90% on room air at rest
  • Serum pregnancy test negative
  • The effects of interferon alpha-2b on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, and because interferons are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • All patients must be informed of the investigational nature of this study and must provide written informed consent in accordance with institutional and federal guidelines; a copy of the informed consent document signed by the patient must be given to the patient

Exclusion Criteria:

  • Patients may not be receiving any investigational agents
  • History of allergic reactions attributed to compounds that are similar to interferon alpha-2b
  • Patients known to be positive for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbsAg) or hepatitis C antibody
  • Patients with organ allografts or immunodeficiency syndromes
  • Patients with prior malignancies may participate provided they have been free of disease for at least 2 years except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; a history of depression in and of itself is not an exclusion to going participating provided the patient and physician believe the depression is controlled and the patient will discontinue the IFN-alpha should symptoms recur
  • Pregnant women are excluded from this study because interferon alpha-2b is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IFN-alpha, breastfeeding should be discontinued if the mother is treated with IFN-alpha
  • Prisoners will be excluded due to the need for multiple timed visits
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01460875
Other Study ID Numbers  ICMJE OSU-07033
NCI-2011-03121 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party William Carson, Ohio State University Comprehensive Cancer Center
Study Sponsor  ICMJE William Carson
Collaborators  ICMJE Schering-Plough
Investigators  ICMJE
Principal Investigator: William Carson, MD Ohio State University
PRS Account Ohio State University Comprehensive Cancer Center
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP